Randolph E Cook

Randy Cook serves as a Contract Specialist within the National Cancer Institute (NCI), part of the National Institutes of Health, where he plays a pivotal role in executing complex research and development acquisitions aligned with the agency’s mission to advance cancer diagnostics, therapeutics, and precision medicine. He manages a diverse portfolio of scientific and technical service contracts, primarily supporting high-capability laboratories and translational research infrastructure. His acquisitions focus on enabling cutting-edge scientific innovation through procurement of analytical platforms, genomic sequencing services, and specialized laboratory support systems, ensuring alignment with federal acquisition regulations and NCI’s strategic research priorities. Cook maintains a strong working relationship with Roche Diagnostics Corporation, a primary contractor providing advanced diagnostic technologies and laboratory systems critical to NCI’s translational research initiatives. His procurement patterns reflect a preference for established industry partners with proven technical capabilities in life sciences, while also engaging a broad base of professional service providers to support specialized research needs. His vendor partnerships are characterized by long-term collaboration, technical alignment, and compliance with rigorous scientific and regulatory standards. His contracting approach prioritizes open competition, with 81.8% of awards issued without set-aside restrictions, reflecting a focus on technical merit and capability over socioeconomic categorization. Nevertheless, he consistently supports small business participation, with 18.2% of awards designated as total small business set-asides under FAR 19.5, demonstrating a balanced commitment to both innovation and economic opportunity. Cook’s procurement focus centers on NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences), where he acquires services related to molecular analysis, biomarker discovery, and clinical data integration. He also procures professional scientific services under NAICS 541990, supporting specialized research operations, and occasionally engages professional organizations under NAICS 813920 to facilitate collaborative scientific initiatives. His expertise lies in securing high-complexity, science-driven solutions that directly advance cancer research outcomes.